Renal Failure News and Research RSS Feed - Renal Failure News and Research

Renal failure or kidney failure is where the kidneys fail to function adequately. Renal failure is divided in acute and chronic forms; either form may be due to a large number of other medical problems.
AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie starts Phase 3 clinical study of atrasentan in patients with diabetic nephropathy

AbbVie announced today the initiation of a Phase 3 clinical study called SONAR (Study Of Diabetic Nephropathy with Atrasentan) to assess the effects of the investigational compound atrasentan - when added to standard of care - on progression of kidney disease in patients with stage 2 to 4 chronic kidney disease and type 2 diabetes. [More]
Leptospirosis: The newest public health threat in Africa

Leptospirosis: The newest public health threat in Africa

The newest public health threat in Africa, scientists have found, is coming from a previously unknown source: the banded mongoose. [More]
Virginia Tech researchers identify leptospirosis as a major health threat in Botswana

Virginia Tech researchers identify leptospirosis as a major health threat in Botswana

The newest public health threat in developing countries may not be a cinematic-quality emerging disease but actually a disease from animals that was identified more than 100 years ago. [More]
Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Merck's LIPTRUZET tablets get FDA approval for treatment of elevated LDL cholesterol

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved LIPTRUZET (ezetimibe and atorvastatin) tablets for the treatment of elevated low-density lipoprotein cholesterol in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet when diet alone is not enough. [More]
Regional anesthesia improves outcomes in sleep apnea patients undergoing total joint arthroplasty

Regional anesthesia improves outcomes in sleep apnea patients undergoing total joint arthroplasty

Using regional anesthesia instead of general anesthesia in patients with sleep apnea undergoing total joint replacement decreases major complications by 17%, according to a study published online, ahead of print, in the journal Regional Anesthesia and Pain Medicine. [More]
Neuraxial anesthesia improves outcomes in patients undergoing hip or knee replacement

Neuraxial anesthesia improves outcomes in patients undergoing hip or knee replacement

A highly underutilized anesthesia technique called neuraxial anesthesia, also known as spinal or epidural anesthesia, improves outcomes in patients undergoing hip or knee replacement, according to a new study by researchers at Hospital for Special Surgery. [More]

Merck, Pfizer sign collaboration agreement for development and commercialization of ertugliflozin

Merck & Co., Inc., known as MSD outside the United States and Canada, and Pfizer Inc. today announced that they have entered into a worldwide (except Japan) collaboration agreement for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor being evaluated for the treatment of type 2 diabetes. [More]

DaVita Hospital Services receives Ambulatory Health Care Accreditation

DaVita, a division of DaVita HealthCare Partners Inc. and a leading provider of kidney care services, today announced that DaVita Hospital Services, the company's inpatient kidney care services, has received Ambulatory Health Care Accreditation from The Joint Commission. [More]
ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma announces results of VP20621 Phase 2 study for preventing recurrent CDI

ViroPharma Incorporated, an international biopharmaceutical company committed to developing and commercializing innovative products that address unmet medical needs and rare diseases, today announced the results of a Phase 2 study of VP20621 (non-toxigenic Clostridium difficile; NTCD) a novel treatment approach for preventing recurrent C. difficile infections. [More]

Good news: Public support increasing for living, deceased organ donation

Good news for anyone needing a transplant; a new Mayo Clinic survey shows that the public's support for both living and deceased organ donation is increasing. [More]
Bioengineered kidneys transplanted into living rats produce urine

Bioengineered kidneys transplanted into living rats produce urine

Bioengineered rat kidneys developed by Massachusetts General Hospital investigators successfully produced urine both in a laboratory apparatus and after being transplanted into living animals. [More]

FDA accepts Otsuka Pharmaceutical's tolvaptan NDA for priority review

Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration has accepted for priority review the company's new drug application for the potential use of tolvaptan for the treatment of autosomal dominant polycystic kidney disease. [More]
NHS intravenous (IV) fluids: an interview with Dr Ian Roberts, LSHTM

NHS intravenous (IV) fluids: an interview with Dr Ian Roberts, LSHTM

Saline is just salty water, whereas colloids are solutions that have large molecules in them. In this case, the molecules are starch. The idea is that because these molecules are big they don’t leak out of the circulation as much. [More]
Researchers identify enzymes that activate coronavirus for infection

Researchers identify enzymes that activate coronavirus for infection

Scientists all over the world are on a quest for an antidote since the first patient died from the new coronavirus in summer 2012. Infection Researchers from the German Primate Center have now identified enzymes that activate the virus for infection. [More]

Aliskiren and standard therapy not associated with reduced CV death or HF rehospitalization

Among patients hospitalized for heart failure (HF) with reduced left ventricular ejection fraction (LVEF; a measure of how well the left ventricle of the heart pumps with each contraction), initiation of the medication aliskiren in addition to standard therapy did not reduce cardiovascular death or HF rehospitalization at 6 or 12 months after discharge, according to a study published online by JAMA. [More]
PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

PsiOxus completes enrollment in MT-102 Phase II trial on cancer cachexia

PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, has completed patient enrollment for its Phase II clinical trial to study MT-102, a small molecule therapeutic for the treatment of cancer cachexia. [More]
Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka receives FDA approval for ABILIFY MAINTENA to treat schizophrenia

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announced the U.S. Food and Drug Administration (FDA) has approved ABILIFY MAINTENA (aripiprazole) for extended- release injectable suspension, an intramuscular (IM) depot formulation indicated for the treatment of schizophrenia. [More]
Starch-based intravenous fluids cause unnecessary deaths in seriously ill patients

Starch-based intravenous fluids cause unnecessary deaths in seriously ill patients

Starch-based intravenous (IV) fluids used by the NHS to treat seriously ill patients are causing unnecessary deaths, according to a new Cochrane systematic review by researchers at the London School of Hygiene & Tropical Medicine. [More]

FDA approves new vial size for CSL Behring’s Privigen to treat primary immunodeficiency

CSL Behring today announced that the United States Food and Drug Administration has approved a 40 g (400 mL) vial size for Privigen, immune globulin intravenous [human]. [More]

Hydroxyethyl starch associated with increased risk of death and acute kidney injury

In an analysis of studies that examined critically ill patients requiring an increase in blood fluid volume, intravenous use of the fluid hydroxyethyl starch was not associated with decreased mortality, according to an article appearing in the February 20 issue of JAMA. [More]